Insider Trading June 17, 2026 10:04 PM

Palantir Director Alexander Moore Offloads $2.1M in Shares Amid Valuation Debates

Insider transaction aligns with pre-arranged plan as analysts weigh AI growth against steep pricing.

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
PLTR

Palantir Technologies Inc. (NASDAQ:PLTR) director Alexander D. Moore executed a sale of 16,000 Class A Common Stock shares on June 15, 2026, totaling $2,133,605. The transaction, conducted via a Rule 10b5-1 trading plan established in December 2025, reduces his direct holdings to 1,111,095 shares. This sale occurs as the stock trades near its 52-week low, with market analysts offering mixed perspectives on the company's valuation and future prospects.

Palantir Director Alexander Moore Offloads $2.1M in Shares Amid Valuation Debates
PLTR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Palantir director Alexander Moore sold 16,000 shares for $2.13 million via a pre-arranged trading plan, leaving him with 1,111,095 shares.
  • Analysts are divided on valuation, with Wolfe Research upgrading to Peerperform citing AI strength, while InvestingPro flags a high P/E ratio of 149.
  • Corporate governance changes include CFO David Glazer joining Playlist's board, alongside a UK contract review and a Google Cloud partnership.

Palantir Technologies Inc. (NASDAQ:PLTR) director Alexander D. Moore has completed a significant divestment of company stock, selling 16,000 shares of Class A Common Stock on June 15, 2026. The transaction, which generated proceeds of $2,133,605, was executed across multiple open market trades. The shares were sold at prices ranging from $129.85 to $134.92 per share. This sale was facilitated through a Rule 10b5-1 trading plan, a pre-arranged framework for buying and selling stock that Moore established on December 11, 2025. Following this transaction, Moore's direct ownership in Palantir Technologies Inc. Class A Common Stock stands at 1,111,095 shares.

The timing of this insider sale coincides with a period of price consolidation for Palantir Technologies. The stock was trading at $130.63, a level close to its 52-week low of $122.68. Over the preceding six months, the stock has declined by 30%, reflecting broader market pressures or sector-specific adjustments. According to analysis from InvestingPro, the company's current valuation metrics suggest it may be overvalued at these levels. The analysis highlights a price-to-earnings (P/E) ratio of 149, indicating a high premium relative to earnings. Investors are directed to additional metrics and tips to further assess Palantir's valuation and performance outlook.

Despite the recent price weakness and insider selling activity, institutional analysts maintain a generally positive outlook on Palantir's strategic position. Wolfe Research recently upgraded Palantir's stock rating from Underperform to Peerperform. The firm cited the company's strong positioning within the artificial intelligence market, emphasizing its exceptional product-market fit and rapid growth within the enterprise AI software sector. Meanwhile, UBS has maintained its Buy rating for Palantir, though the firm noted concerns regarding potential competition from AI research laboratories. Rosenblatt also reiterated a Buy rating, pointing to recent customer wins and an expanded partnership with Google Cloud announced during Palantir's AIPCon 10 event.

Regulatory and corporate governance developments have also marked recent activity for Palantir. UK Prime Minister Keir Starmer announced a review of Palantir's contract with the National Health Service, introducing a layer of political scrutiny to the company's public sector operations. In corporate governance news, Playlist has appointed Palantir's Chief Financial Officer, David Glazer, to its Board of Directors. These moves reflect ongoing strategic shifts and interest within the Palantir ecosystem. The stock closed at 130.63, down 2.62 points or 1.97%, with after-hours trading showing a gain of 1.92 points to 132.55.

Risks

  • Palantir faces potential competition from AI research labs, as noted by UBS, which could impact its enterprise software growth.
  • The company's contract with the UK National Health Service is under review by Prime Minister Keir Starmer, introducing regulatory uncertainty.
  • The stock's high P/E ratio of 149 suggests valuation risks, particularly as the share price trades near its 52-week low.

More from Insider Trading

Alliance Laundry COO Executes $1.92 Million Stock Sale Under Pre-Arranged Plan Jun 17, 2026 Star Equity Holdings CEO Jeffrey Eberwein Acquires Additional Shares Amid Market Activity Jun 17, 2026 Seacoast Banking Director Dennis Hudson Offloads $251K in Shares Amid Mixed Q1 Earnings Jun 17, 2026 Kestra Medical CEO Executes Pre-Arranged Sale of $312,142 in Stock Jun 17, 2026 United Therapeutics CEO Executes Pre-Arranged Stock Sales Under 10b5-1 Plan Jun 17, 2026